These days, the company is strongly inclined to sell or spin off its diagnostics business. Commissiong says the unit will be bringing in “much more qualitative revenue than quantitative revenue in the nearterm,” and the revenue will be insufficient to support therapeutic portfolio development, which is much more expensive than developing diagnostics.

Well, here's the gentle let down for anybody expecting big news during the JP Morgan conference. We all remember how well the "qualitative" data worked out for lympro. This is beyond absurd, the only quality that matters when it comes to revenue is the QUANTITY. Maybe we're bartering off the diagnostics in exchange for something to help us with development of the other assets. Whatever the case, it does not sound like we will be getting much of what we desperately need...CASH.